Monoferric (Ferric Derisomaltose) Patent Expiration, LOE Window & CMS Spending

Monoferric (Ferric Derisomaltose) by Pharmacosmos As: FDA Orange Book core substance LOE 2029-08-14 (last listed 2036-06-22), 0 AB generics, $16.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPharmacosmos As
FDA Application & PathwayN208171 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2029-08-14
Last Listed Patent or Exclusivity Date2036-06-22
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$16.2M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$16.2M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 39.7% 2-yr change)